Randomised, double-blind, placebo-controlled phase IIIb study investigating changes in immunological parameters and cutaneous reactivity induced by a short course immunotherapy with ALK grass tablets [Grazax]
Phase of Trial: Phase III
Latest Information Update: 04 Mar 2008
At a glance
- Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
- Indications Allergic rhinitis; Grass pollen hypersensitivity
- Focus Therapeutic Use
- Sponsors ALK-Abello
- 31 Aug 2018 Biomarkers information updated
- 04 Mar 2008 Status changed from in progress to completed.
- 24 Jul 2007 Status changed from initiated to in progress.